Abstracts tagged "Jak inhibitor"

Abstract Number: 1209 • ACR Convergence 2021
Plasma Calprotectin as a Biomarker of Active Synovitis in Rheumatoid Arthritis: A Clinical and Ultrasound Study in Patients Treated with Il6 and JAK Inhibitors
Beatriz Frade-Sosa¹, Andrés Ponce², Roberto Gumucio³, José inciarte-Mundo⁴, María Torradeflot⁵, Virginia Ruiz-Esquide³, Rosa Morlà², Ana Belén Azuaga⁶, Núria Sapena², Marta Bassas², Julio Ramirez³, Juan D Cañete⁶, Jose A Gomez-Puerta¹ and Raimon Sanmarti¹, ¹Hospital Clínic de Barcelona, Barcelona, Spain, ²Rheumatology Department, Hospital Clínic, Barcelona, Spain, ³Rheumatology departmen. Hospital Clinic de Barcelona, Barcelona, Spain, ⁴Institut d'Investigacions Biomèdiques August Pi i Sunyer,( IDIBAPS), Barcelona, Spain, ⁵Immunology Department, Centre de Diagnòstic Biomèdic, Hospital Clínic de Barcelona, Universitat de Barcelona, IDIBAPS, Barcelona, Spain, ⁶Rheumatology Department, Hospital Clinic, Barcelona, Spain
Background/Purpose: IL6 inhibitors (IL6i) have a dramatic effect on acute phase reactants (AFR) such as C reactive protein (CRP) in rheumatoid arthritis (RA). However, CRP…
Abstract Number: 1545 • ACR Convergence 2021
Safety of JAK Inhibitor in Patients with Rheumatoid Arthritis Who Developed Reactivation of Herpes Zoster Virus After Receiving JAK Inhibitor
Wonho Choi¹, Soo Min Ahn², Yong Gil Kim¹, Chang-Keun Lee¹, Bin Yoo² and Seokchan Hong¹, ¹Asan Medical Center, Seoul, Republic of Korea, ²ASAN MEDICAL CENTER, Seoul, South Korea
Background/Purpose: Janus kinase inhibitor (JAKi) increases the risk of the reactivation of herpes zoster (HZ) virus and may thus be temporarily discontinued in cases of…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].